Injectable opportunities for CMOs despite internal capacity of big pharma sponsors
Pharmaceutical Technology
AUGUST 16, 2022
Even giant pharma companies with large internal production capabilities are leaning on outsourcing to meet market demand for huge numbers of injectables, including high-value biologics and Covid-19 vaccines, according to a GlobalData analysis. Outsourcing may also be pursued if it is more favourable in terms of time and/or cost.
162 
Let's personalize your content